Format

Send to

Choose Destination
Innate Immun. 2015 Aug;21(6):626-34. doi: 10.1177/1753425915575078. Epub 2015 Mar 5.

Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.

Author information

1
Institute of Experimental Immunology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
2
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.
3
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada ashkara@mcmaster.ca.

Abstract

NK cells play a vital role in innate anti-tumor immunity. Crosstalk between NK cells and dendritic cells (DCs) has come to the forefront in protection against tumors in the context of DC vaccines. We previously discovered that NK cell activation mediates the anti-tumor activity elicited by DC vaccines in response to melanoma tumor challenge in a murine lung metastasis model. In this study, we sought to explore the mechanism behind this NK-DC communication, specifically looking at the involvement of IL-15 and type I IFN signaling. Using DCs from IL-15(-/-) and IL-15Rα(-/-) mice, we found that the anti-tumor effect of the vaccine remained comparable with DCs from wild type mice. Moreover, DCs derived from IFN-α/βR(-/-) mice also maintained their anti-tumor effect. Interestingly, endogenous DCs were found to accumulate in the draining lymph nodes post-immunization and their depletion abolished the anti-tumor effect of the vaccine. Our findings suggest the important role that type I IFN signaling and endogenous DCs play in DC vaccine-mediated anti-tumor protection. Our data suggest that type I IFNs from vaccine DCs activate host DCs to provide NK cell-mediated anti-tumor immunity.

KEYWORDS:

DC vaccine; IL-15; IL-15Ra; NK cells; Type I interferon

PMID:
25749844
DOI:
10.1177/1753425915575078
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center